Clinical Trials Search
A Phase II Trial With Safety Run-In Of Neoadjuvant Therapy With An Aromatase Inhibitor In Combination With Durvalumab (Medi4736) In Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.
Primary Objective To evaluate the efficacy of an aromatase inhibitor with durvalumab
AMP-514 (Durvalumab); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Durvalumab (); Exemestane (); Femara (Letrozole); Letrozole (); MEDI4736 (Durvalumab)